ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
The objective of the study is to investigate the safety and efficacy of ONO-4538 in subjects with stage IIIB/IV or recurrent non-small cell lung cancer unsuited to radical radiotherapy and resistant to a platinum-based chemotherapeutic regimen.
Advanced Non-small Cell Lung Cancer
DRUG: ONO-4538
Safety (Adverse events, Laboratory tests, Vital signs, ECG, Chest X-ray, ECOG), Approximately 6 months
Response rate (centrally assessed), Approximately 6 months|Response rate (study site assessment by investigator), Approximately 6 months|Overall survival, Approximately 1 year
The objective of the study is to investigate the safety and efficacy of ONO-4538 in subjects with stage IIIB/IV or recurrent non-small cell lung cancer unsuited to radical radiotherapy and resistant to a platinum-based chemotherapeutic regimen.